Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BBIO Stock Forecast 2026-2027
$67.98
Current Price
$13.18B
Market Cap
Buy 21
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BBIO Price Targets
+131.0%
To High Target of $157.00
+42.0%
To Median Target of $96.50
+17.7%
To Low Target of $80.00
BBIO Price Momentum
+4.0%
1 Week Change
-9.7%
1 Month Change
+110.4%
1 Year Change
-11.1%
Year-to-Date Change
-20.0%
From 52W High of $84.94
+140.0%
From 52W Low of $28.33
📊 TOP ANALYST CALLS
Did BBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bridgebio is one of their latest high-conviction picks.
Latest BBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 28 Wall Street analysts, BBIO has a bullish consensus with a median price target of $96.50 (ranging from $80.00 to $157.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $67.98, the median forecast implies a 42.0% upside. This outlook is supported by 21 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Eliana Merle at Barclays, suggesting a 17.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BBIO Analyst Ratings
21
Buy
1
Hold
0
Sell
BBIO Price Target Range
Low
$80.00
Average
$96.50
High
$157.00
Current: $67.98
Latest BBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 10, 2026 | JP Morgan | Anupam Rama | Overweight | Maintains | $94.00 |
| Mar 10, 2026 | William Blair | John Boylan | Outperform | Initiates | $N/A |
| Feb 25, 2026 | Morgan Stanley | Sean Laaman | Overweight | Maintains | $98.00 |
| Feb 25, 2026 | Evercore ISI Group | Cory Kasimov | Outperform | Maintains | $125.00 |
| Feb 25, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $95.00 |
| Feb 25, 2026 | Oppenheimer | Trevor Allred | Outperform | Maintains | $81.00 |
| Feb 17, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $100.00 |
| Feb 13, 2026 | Wells Fargo | Derek Archila | Overweight | Maintains | $98.00 |
| Feb 13, 2026 | Oppenheimer | Trevor Allred | Outperform | Maintains | $83.00 |
| Jan 28, 2026 | Barclays | Eliana Merle | Overweight | Initiates | $80.00 |
| Jan 20, 2026 | Wells Fargo | Derek Archila | Overweight | Maintains | $88.00 |
| Jan 8, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $86.00 |
| Jan 6, 2026 | Morgan Stanley | Sean Laaman | Overweight | Initiates | $96.00 |
| Dec 15, 2025 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $86.00 |
| Dec 11, 2025 | Bernstein | William Pickering | Outperform | Initiates | $94.00 |
| Nov 11, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $84.00 |
| Nov 7, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $77.00 |
| Nov 3, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $90.00 |
| Oct 31, 2025 | Goldman Sachs | Paul Choi | Buy | Maintains | $100.00 |
| Oct 30, 2025 | Piper Sandler | Biren Amin | Overweight | Maintains | $98.00 |
BridgeBio Pharma Inc. (BBIO) Competitors
The following stocks are similar to Bridgebio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BridgeBio Pharma Inc. (BBIO) Financial Data
BridgeBio Pharma Inc. has a market capitalization of $13.18B with a P/E ratio of -18.0x. The company generates $502.08M in trailing twelve-month revenue with a -144.4% profit margin.
Revenue growth is +2,521.2% quarter-over-quarter, while maintaining an operating margin of -83.3% and return on equity of +34.9%.
Valuation Metrics
Market Cap
$13.18B
Enterprise Value
$15.69B
P/E Ratio
-18.0x
PEG Ratio
0.6x
Price/Sales
27.6x
Growth & Margins
Revenue Growth (YoY)
+2,521.2%
Gross Margin
+94.7%
Operating Margin
-83.3%
Net Margin
-144.4%
EPS Growth
+2,521.2%
Financial Health
Cash/Price Ratio
+4.5%
Current Ratio
2.8x
Debt/Equity
-0.9x
ROE
+34.9%
ROA
-33.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BridgeBio Pharma Inc. (BBIO) Business Model
About BridgeBio Pharma Inc.
What They Do
Develops transformative medicines for genetic diseases.
Business Model
BridgeBio Pharma utilizes a decentralized hub-and-spoke model, allowing autonomous teams to focus on specific disease conditions while leveraging a central hub for clinical, regulatory, and commercial support. The company generates revenue through its commercial-stage products and potential partnerships with academic institutions to advance early-stage research, focusing on first-in-class treatments for underserved populations.
Additional Information
BridgeBio's pipeline includes innovative therapies for various genetic disorders and cancers, positioning it as a leader in precision medicine. Its unique approach enables targeted treatment strategies for rare genetic conditions, addressing significant unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
834
CEO
Dr. Neil Kumar Ph.D.
Country
United States
IPO Year
2019
Website
bridgebio.comBridgeBio Pharma Inc. (BBIO) Latest News & Analysis
Latest News
Quick Summary
BridgeBio's stock increased following developments in the patent dispute related to Pfizer's competing drug, tafamidis.
Why It Matters
BridgeBio's stock surge indicates investor optimism about potential market share gains from Pfizer's drug setback, signaling a favorable shift in competitive dynamics.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
William Blair has begun coverage of a commercial-stage biotech firm, noting its growing pipeline focused on treatments for rare genetic conditions.
Why It Matters
William Blair's coverage signals potential growth for the biotech firm, emphasizing its expanding pipeline, which could lead to increased revenue and investor interest in the company.
Source: Benzinga
Market Sentiment:
Positive
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress
1 day ago
Quick Summary
Limb-girdle muscular dystrophy type R9 (LGMDR9) is a rare genetic disorder linked to mutations in the FKRP gene.
Why It Matters
The identification of LGMDR9 and its genetic basis may drive interest in biotech investments focused on rare disease treatments and gene therapies, potentially impacting stock valuations in the sector.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
BridgeBio Pharma, Inc. (BBIO) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting key developments and strategies to investors.
Why It Matters
BridgeBio Pharma's presentation at a major healthcare conference could signal strategic developments or insights that may influence stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Phase 3 FORTIFY interim results show BBP-418's broad and consistent efficacy across key clinical endpoints and subgroups, presented at MDA.
Why It Matters
Positive Phase 3 results for BBP-418 indicate strong efficacy, potentially boosting investor confidence and interest in the company’s future performance and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BridgeBio Pharma will present additional interim analysis data from its Phase 3 trial of BBP-418 for LGMD2I/R9 at the MDA Conference on March 8-11, 2026, alongside academic findings.
Why It Matters
BridgeBio's upcoming presentation of Phase 3 trial data for BBP-418 could significantly impact its stock price, reflecting investor sentiment on its potential for treating LGMD2I/R9.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BBIO Stock
What is BridgeBio Pharma Inc.'s (BBIO) stock forecast for 2026?
Based on our analysis of 28 Wall Street analysts, BridgeBio Pharma Inc. (BBIO) has a median price target of $96.50. The highest price target is $157.00 and the lowest is $80.00.
Is BBIO stock a good investment in 2026?
According to current analyst ratings, BBIO has 21 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $67.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BBIO stock?
Wall Street analysts predict BBIO stock could reach $96.50 in the next 12 months. This represents a 42.0% increase from the current price of $67.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BridgeBio Pharma Inc.'s business model?
BridgeBio Pharma utilizes a decentralized hub-and-spoke model, allowing autonomous teams to focus on specific disease conditions while leveraging a central hub for clinical, regulatory, and commercial support. The company generates revenue through its commercial-stage products and potential partnerships with academic institutions to advance early-stage research, focusing on first-in-class treatments for underserved populations.
What is the highest forecasted price for BBIO BridgeBio Pharma Inc.?
The highest price target for BBIO is $157.00 from at , which represents a 131.0% increase from the current price of $67.98.
What is the lowest forecasted price for BBIO BridgeBio Pharma Inc.?
The lowest price target for BBIO is $80.00 from Eliana Merle at Barclays, which represents a 17.7% increase from the current price of $67.98.
What is the overall BBIO consensus from analysts for BridgeBio Pharma Inc.?
The overall analyst consensus for BBIO is bullish. Out of 28 Wall Street analysts, 21 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $96.50.
How accurate are BBIO stock price projections?
Stock price projections, including those for BridgeBio Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 7:05 AM UTC